Ovarian reserve testing has become a significant part of the fertility conversation for many women over 35. Whether you’ve encountered a low AMH number in a fertility workup, had a healthcare provider mention “diminished ovarian reserve,” or are simply trying to understand what these tests measure before you pursue them, understanding what ovarian reserve actually reflects—and what it doesn’t—can provide important context.
The terminology in this area can be confusing, and the emotional weight attached to these numbers is often considerable. Research on the subject has both clarified and complicated our understanding of ovarian reserve as a fertility marker, and the nuances matter when it comes to interpreting results meaningfully.
This article provides a research-informed overview of the main ovarian reserve tests, what they measure, how to interpret results, and what they can and cannot tell you about your fertility.
What Ovarian Reserve Actually Means
Ovarian reserve refers to the quantity and, to some extent, the quality of the remaining egg supply within the ovaries. Women are born with all the eggs they will ever have—approximately 1–2 million at birth—and this number declines throughout life through a process of natural attrition. By puberty, roughly 300,000–500,000 eggs remain; at menopause, the remaining reserve is functionally depleted.
After approximately age 37, the rate of egg loss accelerates and egg quality (chromosomal integrity) also tends to decline. Research from PubMed/NIH indicates that ovarian reserve markers decrease steadily with age, though the pace of this decline varies considerably among individuals—some women in their late 30s have reserve comparable to the average woman in her early 30s, while others decline more rapidly.
Understanding ovarian reserve is important because it can inform fertility treatment planning and help set realistic expectations about timelines and approaches. However, ovarian reserve is a measure of egg quantity and does not directly measure egg quality, uterine function, fallopian tube patency, or other factors that also contribute to fertility outcomes.
Anti-Müllerian Hormone (AMH): The Primary Ovarian Reserve Marker
AMH is a protein produced by the granulosa cells surrounding developing follicles in the ovaries. Its levels in the blood are considered the most reliable continuous marker of ovarian reserve currently available, largely because AMH remains relatively stable throughout the menstrual cycle—unlike FSH and estradiol, which fluctuate depending on cycle day.
How AMH Is Measured
AMH is assessed through a blood test and can technically be taken on any day of the menstrual cycle. Results are typically reported in nanograms per milliliter (ng/mL) or picomoles per liter (pmol/L), and reference ranges vary between laboratories. Interpreting AMH results requires knowing which laboratory and assay was used, as values are not universally standardized.
What Low AMH Does and Doesn’t Mean
A low AMH result indicates that the remaining egg supply may be reduced relative to age-matched averages. However—and this is important—low AMH is not synonymous with inability to conceive, particularly for natural conception. Research has found that in women with regular ovulatory cycles, AMH is not a reliable predictor of the probability of natural conception within a given timeframe. AMH’s predictive value is stronger for IVF outcomes (specifically egg yield from stimulation) than for natural conception probability. As explored in our article on trying to conceive after 37, ovarian reserve is one piece of a much larger fertility picture.
Antral Follicle Count (AFC): The Ultrasound Measure
The antral follicle count (AFC) is measured via transvaginal ultrasound, typically in the early follicular phase (cycle days 2–4). It counts the number of small, resting follicles (2–10 mm) visible in both ovaries—these antral follicles represent the pool from which a dominant follicle will be recruited each cycle.
AFC correlates reasonably well with AMH and declines with age. A higher AFC is generally associated with a larger ovarian reserve and a better response to fertility treatment stimulation. Like AMH, AFC has known limitations as a standalone predictor of natural conception outcomes—it is most informative as part of a comprehensive fertility evaluation that also includes other hormonal markers and a uterine assessment.
The combination of AMH and AFC, interpreted together with other fertility markers by an experienced reproductive endocrinologist, provides a more complete picture of ovarian reserve than either test alone.
FSH and Estradiol: The Day 3 Hormones
Follicle-stimulating hormone (FSH) and estradiol are measured on approximately day 3 of the menstrual cycle and have historically been among the primary ovarian reserve assessments. FSH from the pituitary signals the ovaries to stimulate follicle development; when the ovaries have fewer follicles to respond to, FSH tends to rise—so elevated FSH on day 3 is associated with diminished ovarian reserve.
However, FSH fluctuates significantly between cycles and can be normal in one cycle and elevated in the next. A single normal FSH reading does not guarantee that reserve is adequate, and a single elevated reading should be interpreted cautiously. The context of estradiol is also important—if estradiol is elevated on day 3, it may suppress FSH, making an FSH result appear falsely normal. For this reason, day 3 FSH is typically interpreted alongside estradiol, and trend data across multiple cycles can be more informative than a single measurement. Learn more about hormonal testing in the context of fertility evaluation in our guide to hormonal markers after 35.
Understanding “Diminished Ovarian Reserve” as a Diagnosis
Diminished ovarian reserve (DOR) is a clinical term used when ovarian reserve markers—particularly AMH, AFC, and/or FSH—fall outside the ranges considered normal for a given age. It is a description of test results relative to population norms, not a definitive statement about an individual’s fertility potential.
DOR is a spectrum, not a binary. Women who receive this diagnosis range from those who are at the lower end of a normal range to those with severely reduced markers. The clinical implications and what, if anything, to do about them depend on the individual’s full fertility picture, age, overall health, and reproductive goals.
Research on outcomes for women with DOR who are trying to conceive shows considerable variation. Some women conceive naturally despite low reserve markers; others require fertility treatment; and for some, especially those with very low markers at older ages, achieving pregnancy with their own eggs is more challenging. Discussing your specific numbers with a reproductive endocrinologist—rather than interpreting them in isolation—is essential for understanding what they mean for your individual situation.
When to Get Ovarian Reserve Testing
Ovarian reserve testing is typically part of a comprehensive fertility evaluation, which current guidelines suggest considering after 6 months of trying to conceive for women aged 35–37, or after 3 months for women 38 and older. Testing may also be appropriate for women who want to understand their ovarian reserve before actively trying to conceive, as part of family planning conversations.
According to the American College of Obstetricians and Gynecologists, ovarian reserve testing provides the most actionable information in the context of fertility planning—not as a general health screening tool for women who are not planning pregnancy. The decision to pursue testing should be made in discussion with your gynecologist or reproductive endocrinologist.
🔮 Related Product Guide
If you’re tracking your cycle, our guide to ovulation test kits for women over 35 compares the most-reviewed options — from basic LH strips to quantitative hormone monitors — with context on what may matter more when cycles are shorter or less predictable after 35.
Frequently Asked Questions
If my AMH is low, does that mean I can’t get pregnant naturally?
No. Low AMH is associated with a reduced egg supply, but research suggests it does not reliably predict the probability of natural conception in women who are ovulating regularly. Many women with low AMH conceive naturally. The clinical significance of a low AMH result depends on your complete fertility picture, including whether you are ovulating, your age, and other factors—best interpreted by a reproductive endocrinologist.
Can ovarian reserve be improved?
Current scientific evidence does not support the claim that any supplement, lifestyle change, or treatment can meaningfully increase ovarian reserve (the number of eggs). Some research has explored approaches aimed at egg quality rather than quantity—such as the role of coenzyme Q10—but evidence remains preliminary and these are not established treatments. Be cautious of products or services claiming to “boost” ovarian reserve, as the evidence base is generally weak. Discussing any supplements you’re considering with your reproductive endocrinologist before starting is advisable.
How often should ovarian reserve be tested?
There is no established standard for how frequently ovarian reserve testing should be repeated. In the context of fertility treatment planning, markers may be re-assessed periodically. For women who have received a DOR diagnosis and are deciding on treatment approach, following up with a reproductive endocrinologist on a timeline they recommend is the most practical guidance.
Is ovarian reserve testing appropriate before age 35?
Testing may be appropriate at any age in the context of specific circumstances—such as a family history of premature ovarian insufficiency, prior ovarian surgery, or autoimmune conditions that may affect the ovaries. For women without specific risk factors who are not planning pregnancy in the near future, the value of routine ovarian reserve testing is less established, and a conversation with your gynecologist can help determine whether it’s indicated for your situation.
Key Takeaways
- Ovarian reserve tests—including AMH, AFC, and day 3 FSH—measure egg quantity, not directly egg quality, and provide one piece of a multifaceted fertility picture.
- Low AMH is not predictive of natural conception inability in women who are ovulating; its strongest predictive value is for IVF egg yield rather than natural conception probability.
- Ovarian reserve markers are best interpreted by a reproductive endocrinologist in the context of a full fertility evaluation, including other hormonal markers and clinical history.
- Current evidence does not support claims that supplements or lifestyle changes can meaningfully increase ovarian reserve quantity.
- Seeking a comprehensive fertility evaluation after 3–6 months of trying to conceive at age 35 or older is consistent with current clinical guidelines and can provide personalized, actionable information.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.